Phase I favorable results for TiGenix’ sepsis drug

June 8, 2015 News BioVox


TiGenix is developing a drug based on allogeneic expanded adipose-derived stem cells (eASCs) to treat artritis and sepsis. The Phase I trials confirmed the safety and tolerability of the drug. The drug was administered via intravenous injection to patients with sepsis, after it showed a favorable safety and tolerability profile in patients with arthritis. The efficacy in significantly reducing mortality has been demonstrated in several animal models of sepsis through a combination of reduced inflammation, production of anti-microbial effectors, and increased phagocytosis.
Investors reacted, enthusiastically resulting in a profit of 1,67% on the stock market.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter